• Americans with higher levels of education are more likely to vote, to volunteer, to donate to charity, article reports
• Company has disrupted the education paradigm, creating a game-changing Discovery Learning System
• Emaginos offers an actionable plan to transform and improve public schools rather than replace them

The ultimate impact of a quality education is almost impossible to measure, although studies and research start to tell the story, reporting numbers and facts that make it hard to not make education a priority. Emaginos Inc., a company dedicated to transforming K-12 public schools through a model composed of integrated proven best practices, is committed to providing the best education available to the upcoming generation. “There is no question that education is a powerful driver of prosperity,” states an article from the Center for American Progress (https://ibn.fm/0k4lj). “Americans with college degrees earn 117 percent more a year than those who do not complete high school. Based on data for the high school class of 2015, raising the nation’s high school graduation rate from 83 percent to 90 percent would result in an additional $3.1 billion in earnings for each high school cohort, which would translate into a $5.7 billion increase in gross domestic product. Moreover, Americans with higher levels of education are more likely to vote, to volunteer, and to donate to charity.” Although not everyone may be aware of those facts, few would argue that education is not essential. However, what constitutes a quality education is often the question. Emaginos offers the answer. The innovative education-based company has disrupted the education paradigm, building a game-changing Discovery Learning System (“DLS”) that offers a systemic transformation from the current teacher-centered model to a K-12 public education system focused on fostering a student’s desire to learn. While the company acknowledges the current public education system is broken, it also is committed to maintaining, and in some cases restoring, the concept of neighborhood schools being the heart of a community. Emaginos is the first company with an actionable plan to transform and improve public schools rather than replace them. The Emaginos model utilizes existing funding, facilities and staff to improve educational approaches and outcomes, in many cases saving school districts money as they subscribe to and implement the Emaginos platform. The transformation starts with one school in a school district adopting the Emaginos DLS, serving as a model for the district’s conversion to the Emaginos platform. The pilot school is used to test and demonstrate the effectiveness and efficacy of a new model in the district. After successful implementation of the Emaginos model at the pilot location, lessons learned during the conversion process at the pilot school inform the implementation of the Emaginos model districtwide. As part of the process, Emaginos provides a wide range of resources, from technology infrastructure and curriculum to training and other services, which enables school districts to successfully implement the proven Emaginos plan. The transformed schools operate for the same or less cost than their previous model, resulting in a much better education for the same or a lower cost. The time for investing in better education has never been more urgent as the impact a quality education has on people individually and society as a whole is evident. Emaginos offers a first-to-market, actionable plan that holds promise for the future using existing funding, facilities and staff and without making additional resource demands. For more information, visit the company’s website at www.Emaginos.com. NOTE TO INVESTORS: The latest news and updates relating to Emaginos are available in the company’s newsroom at https://ibn.fm/Emaginos

• PULL subsidiary Pure Mushrooms Corp. opens direct-to-consumer e-Commerce store on Amazon platform
• Store features Reishi, Maitake formulations with plans to add Lion’s Mane in summer 2021
• Global functional mushroom market valued at $25.4 billion in 2020, expected CAGR of 8.44% from 2021-2026
• Company expands psychedelic vertical through letter of intent with Psyence Group to co-produce psychedelic mushroom-based psilocybin formulations

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, recently announced that Pure Mushrooms Corp., its wholly owned subsidiary, has opened a direct-to-consumer, e-Commerce store on the Amazon platform to sell its Reishi and Maitake formulations. Marketed under the Pure Mushrooms brand, the Company expects sales to add significantly to 2022 revenue growth and plans to add more formulations alongside increasing functional mushroom market demand. Mordor Intelligence valued the global functional mushroom market at $25.4 billion in 2020 with an expected CAGR of 8.44% from 2021-2026 (https://ibn.fm/2ri8B). The industry has been growing rapidly in recent years with popular uses spanning cognitive enhancement to reducing cancer risk (https://ibn.fm/nMx1d). With an aim to tap into the growing market, Pure Mushrooms’ gluten-free and vegan Reishi and Maitake formulations are priced at just under $20 for 90 capsules, with a planned rollout of its Lion’s Mane formulation this summer. “We are excited to be on Amazon, the largest online marketplace and the most powerful platform in the world for brand development, and to have made our first US and Canadian sales of our Pure Mushrooms products,” said Pure Extracts CEO Ben Nikolaevsky. “The functional mushroom wellness market is experiencing robust sales as many consumers are trying to boost their immune systems in light of the COVID-19 pandemic. As we build out the mushroom extraction section of our facility, we plan to bring more products to market.” Pure Extracts is also making strides in its psychedelic mushrooms vertical through a recently signed letter of intent with the Psyence Group to co-produce psychedelic mushroom-based psilocybin formulations. As one of the world’s first psychedelic mushroom companies, Psyence operates a federally legal commercial cultivation and extraction facility in Southern Africa. With a network based in South Africa, Lesotho, Jamaica – and now Canada – the company aims to rapidly develop natural psychedelics and novel drug delivery systems for patients across the world (https://ibn.fm/kYc3X). Based in British Columbia, Pure Extracts operates out of its state-of-the-art facility built to European Union GMP standards, enabling the Company to obtain EU-GMP certification for export to European countries where its products are legal for sale and consumption. With the market for cannabis, functional and medicinal psychedelic products gaining traction across the world, Pure Extracts is favorably positioned to gain significant market share within the rapidly expanding plant-based medicine industry. For more information, visit the company’s website at www.PureExtractsCorp.com. NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• There is a significant need for EEG diagnostics in pediatric patients, but traditional testing is challenging due to poorly fitting adult-sized equipment, which also increases resistance to testing
• This leaves a considerable gap in neurological care for young patients
• BRSF’s Pediatric NeuroCap steps in to solve major barriers limiting EEG monitoring in pediatric care

There is a significant need for EEG diagnostics in pediatric patients, as children can suffer from neurological conditions, but traditional EEG procedure in this setting is time-consuming, cumbersome, and inconvenient. It means that the benefits of EEG testing in pediatrics could not be fully leveraged, leaving a considerable gap in neurological care for young patients. The gap that Brain Scientific (OTCQB: BRSF), a neurology medical device and software company, is poised to close. The most common neurological disorders in children include febrile seizures, which typically do not require EEG testing. However, for some other conditions, such as febrile status epilepticus, non-convulsive seizures, non-convulsive status epilepticus, and altered mental status of unknown cause, EEG testing is of critical importance. Sometimes, it is difficult to differentiate between the two groups of conditions with widely different outcomes. In many instances, EEG could help medical staff sort through complex differential diagnosis so that urgent treatment can be provided. Still, the logistical barriers to its use in pediatric emergency care often mean that medical professionals have to rely on indirect assessments instead. Fortunately, Brain Scientific is developing new technology that allows EEG to be deployed rapidly and accurately in children and adolescents (https://ibn.fm/iDOLU). Conducting EEG in ICU settings is often a practical challenge. For example, it requires that a portable EEG system is available or that the critically ill patient is transferred to an EEG suite. The latter could often have a detrimental health impact as it involves removing the patient in a severe condition from the urgent care support that serves as the lifeline for those in the most fragile state. It also requires trained EEG technicians to adequately position electrodes after applying gel to each, which takes considerable time. Time is incredibly precious in an urgent setting where every second counts —time spent on diagnosis eats away at the time that could be spent on treatment. It is even more of a struggle to deploy EEG in pediatric patients. A significant complicating factor for EEG testing in pediatrics is that adult equipment is often used for children. This means that it needs to be adjusted to fit a child’s considerably smaller head, which further complicates deployment as electrodes cannot overlap. Placing each electrode may turn into an even bigger challenge as children often resist medical testing. As much as traditional EEG testing is challenging in ideal circumstances, the pandemic has only exacerbated these struggles. The deadly virus can be found on various surfaces and equipment in a medical setting. Reusable EEG electrodes must be disinfected between uses to avoid cross-contamination between patients. This is where the Pediatric NeuroCap steps in to solve significant barriers limiting EEG monitoring in pediatric care (here is a video of the setup). Instead of improvising to make adult-size EEG electrodes fit pediatric patients’ smaller head circumference, Brain Scientific fully adapted its revolutionary NeuroCap to be used in children. The Pediatric NeuroCap comes in two sizes and includes 22 integrated, pre-gelled electrodes compliant with the 10-20 international system. With The Pediatric NeuroCap, the logistical struggle to perform EEG testing in pediatric patients appears on the way to be solved — the testing can be conducted within five minutes by any member of the clinical team. The cap removes the need to place each electrode one by one and is robust enough to sustain resistance to testing often found in pediatric patients. After delivering up to 4 hours of hospital-grade EEG monitoring, pediatric NeuroCap can be removed in less than 1 minute and disposed of, making it an ideal fit for the pandemic environment. The Pediatric NeuroCap is positioned to be the first disposable and pre-gelled headset available for the pediatric market, bringing faster, more efficient, and sanitary brain diagnostics to the pediatric setting. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Imagin Medical Inc. has designed a system to improve the visualization of bladder cancer during minimally invasive surgery that will display, simultaneously, white and blue light images side-by-side, to help surgeons more easily identify and locate cancerous tumors for removal
• The company’s i/Blue Imaging System(TM) has the potential to make bladder cancer detection and removal more efficient and accurate, as well as reduce recurrence rates and health care costs, targeting a global bladder cancer market estimated to reach $4.71 billion by 2026
• The company’s proprietary system has entered the manufacturing stage with their partner Lighthouse Imaging, an FDA registered and ISO 13485:2016 certified manufacturer. Imagin expects to have the final design-for-manufacturing model ready to demonstrate at the American Urological Association (“AUA”) meeting in September 2021

Bladder cancer has a one of the highest recurrence rates, with approximately 50% of patients likely to relapse, making it one of the most prevalent and expensive cancers to treat. A primary contributor to this high recurrence rate is the difficulty surgeons may have in seeing and clearly locating all of the cancerous tumors and their margins. If cancerous cells are missed and not removed, the cancer can recur. Surgeons treating early-stage bladder cancer often use a cystoscope, a long tube with a camera and light at the end, inserted through the urethra to explore the bladder. Using white light illumination, the cystoscope displays the bladder wall as well as protruding (raised) tumors so that the surgeon can see and, with additional instrumentation, remove cancerous tumors. However, some bladder cancer tumors are non-protruding (flat) and their margins may be difficult to see and might be missed by the surgeon. In 2010, a system was introduced that uses a special fluorescing contrast agent, hexaminolevulinate hydrochloride (“HAL”), together with blue light illumination, to cause protruding and flat tumors, as well as their margins, to glow pink, making the cancerous tissue easy to see. Called blue light cystoscopy (“BLC”), this approach offers a significant improvement in bladder cancer detection. Studies show that BLC use can help remove up to 25% more tumors (https://ibn.fm/Jb90R). However, to properly navigate within the bladder the surgeon needs to see the white light image that shows the bladder wall, as well as the blue light image that shows the highlighted cancerous cells. Current technology shows only one image at a time, requiring the surgeon to constantly switch back and forth between the white and blue light images. The switching process makes orientation and navigation withing the bladder a challenge for surgeons. This is one reason that hospitals and doctors have been very slow to adopt BLC, in spite of its significant advantages. That’s what makes Imagin Medical’s (CSE: IME) (OTCQB: IMEXF) patented i/Blue Imaging System(TM) so important. It will directly address this problem by displaying real-time white and blue light images simultaneously, side-by-side, removing the challenge of constantly switching and reorienting. The surgeon will see the bladder wall alongside the cancerous cells, making navigation far easier and more accurate and, overcoming the primary weakness of the traditional BLC system. In addition, unlike current BLC technology the i/Blue Imaging System will adapt to most endoscopes on the market. With this major roadblock removed, Imagin believes its i/Blue Imaging System will expand the adoption of BLC and lead to more successful surgical outcomes, with the potential of and fewer recurrences of this notoriously stubborn and expensive cancer. For more information, visit the company’s website at www.ImaginMedical.com. NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• Infobird has always held that the growth of China’s intelligent customer service industry is contingent on ecological cooperation
• Recently, IFBD inked an ecological cooperation agreement with CESTC furthering its commitment to its long-held stance
• The agreement will help create a customer-centered, mutually beneficial, and symbiotic ecological system that is expected to grow and transform China’s digital economy

Infobird (NASDAQ: IFBD), a Software-as-a-Service (“SaaS”) company offering artificial intelligence (“AI”)-enabled end-to-end customer engagement solutions in China, has always held that the growth of China’s intelligent customer service industry as a whole can only be realized through the dint of cooperation. In a 2020 blog article published on its website (https://ibn.fm/Ixhii), Infobird delineated why it is crucial for upstream manufacturers, midstream technology and product service providers, and downstream system integrators to build a healthy ecology. “Through diversified cooperation ecology,” the article reads, “Infobird shares technology and resources with all partners, integrates China’s most cutting-edge big data and artificial intelligence technology, and continuously penetrates technology into different industries and scenarios with the help of the resource advantages of each partner, realizing the wide application of intelligent customer service software.” It is this approach to building a customer-centered, mutually beneficial, and symbiotic ecological system that guided the company’s recent move. On May 20, Infobird announced it had reached an ecological cooperation agreement with China Electronic System Technology Co., Ltd (“CESTC”), a subsidiary of China Electronics Corporation (https://ibn.fm/xb5be). Through the agreement, IFBD and CESTC will work together in the fields of modern digital cities and credit creation to further the accelerated development of China’s digital economy, leveraging the advantages of both parties to strengthen technology integration and resource interaction. The pair will synergistically work on integrating intelligent quality inspection products, voice chatbots, and cloud call centers into a bevy of scenarios apposite to constructing a digital economy. The agreement brings together companies that, according to IFBD’s description in its article, are within the midstream category of Chinese enterprises. CESTC is a core company in China’s electronic digital and information service industry that provides electronic information service products and services. It is also a major promoter and practitioner of modern digital city business. On its part, Infobird offers unique customer engagement software that merges the capabilities of AI and cloud-native architecture to provide intelligent omnichannel customer service support, AI voice/text chatbot solutions, intelligent telemarketing services, and cloud call center utilities. So advanced is IFBD’s offering that it is the only SaaS company in China that owns and deploys cloud-native architecture in customer engagement (https://ibn.fm/XtBRe). Infobird’s AI-enabled software has been a crucial differentiator in an industry fraught with numerous traditional CRM tools and products. The company intends to use it to help its clients reduce the cost of customer engagement and improve interaction efficiency. Further, IFBD is transitioning to standardized module SaaS to facilitate service and product delivery to various enterprises in China regardless of size, a first in the Chinese SaaS landscape. With IFBD already aiding in the digital transformation and upgrading of enterprises through its operations, the ecological cooperation with CESTC is set to add more momentum into urban digitization and the growth of the digital economy in China. For more information, visit the company’s website at www.Infobird.com/en/index.html. NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD

• Ability to tailor diagnostics, therapeutics to specific patients is key to precision medicine
• Global precision oncology market projected to grow at CAGR of 9.9% over the next eight years, will reach $99.7 billion by 2027
• Varian Bio making significant headway in development of two preclinical experimental cancer drugs

Healthtech Solutions (OTC: HLTT) is making a strong statement with its most recent acquisition. HLTT acquired Varian Biopharmaceuticals, a precision oncology company developing novel therapeutics for the treatment of cancer —and with the acquisition, the company is making its entry into the precision cancer care market (https://ibn.fm/IaAcf). “Precision medicine is a concept that collectively integrates the outcomes and the endeavors of research and healthcare,” states a recent Research and Markets article (https://ibn.fm/PWUBE). “The ability to tailor the diagnostics and therapeutics offered to the patients is the key to precision medicine. The combination of biotechnology development, digitization of health care, and public investment led to the evolution of the personalization of disease-based therapies. “This evolution within precision medicine will profoundly impact the biopharmaceutical industry,” continued the article. “Multiple players from biopharma to diagnostics companies with multiple functions such as research and development to commercial operations will witness a change.” A Precision Oncology Market analysis by Reports and Data noted that the global precision oncology market size totaled an estimated $49.9 billion in 2019; the report projects that the market will grow at a CAGR of 9.9%   to reach $99.7 billion by 2027 (https://ibn.fm/LMNjX). Led by its newest acquisition, Healthtech Solutions is positioning itself to be a leader in that burgeoning space. Varian Bio is developing a proprietary atypical protein kinase C iota (aPKCi) inhibitor for the treatment of various tumor types. Specifically, the company is making headway in the development of two preclinical experimental cancer drugs: VAR-101, a topical formulation for the treatment of basal cell carcinoma, the most common form of skin cancer (https://ibn.fm/S7Ntz); and VAR-102, an oral formulation being evaluated for treatment of a variety of solid tumors, including pancreatic, colorectal and non-small cell lung cancer (“NSCLC”). “Varian Bio is at the leading edge of cancer treatment technology, and it is an honor to have them join our portfolio,” said Healthtech Solutions chairman David Rubin. “The fact that they are developing therapies to target difficult-to-treat cancers such as pancreatic cancer demonstrates just how innovative their team is. Precision oncology is an exciting field, and we’re thrilled to be a part of it.” Varian Bio’s drug candidates — VAR-101 and VAR-102 — leverage the company’s expertise. In addition to the strides the company is making in precision oncology, HealthTech is also developing technology that can transform 2D images from a portable ultrasound machine into digital 3D images to provide better diagnosis and more accurate internal trauma views. The technology, being developed by subsidiary Medi-Scan Inc., has multiple applications in lung, cardiac and musculoskeletal imaging and related uses. For more information, visit the company’s website at www.HealthTechSolutions.com. NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://ibn.fm/HLTT

• Asia Broadband recently released Q1 2021 results featuring a strong balance sheet as indicated by over $100 million in total assets, an increase of 283% from a similar period last year
• The results signal AABB’s highly liquid position to fully fund and rapidly grow its gold mining and cryptocurrency operations
• AABB intends to acquire high-yield gold mining assets to increase its physical gold holdings
• AABB recently hired a marketing firm to design an international marketing campaign to be rolled out in May

Asia Broadband (OTC: AABB), a company that utilizes its specific geographic expertise, experience, and extensive industry contacts to facilitate its innovative distribution process from the production and supply of base and precious metals in Mexico to its client sales networks in Asia, recently published its Q1 2021 results, featuring positives, including a highly liquid financial position, that set a strong foundation for growth in 2021 (https://ibn.fm/1nVtj). As part of the published Q1 2021 results for the three months ending March 31, 2021, AABB’s balance sheet featured $106.4 million in total assets, compared to $27.8 million reported for Q1 2020 and a total of $48.7 million reported for the FY 2020, marking a 283% and a 119% increase, respectively. According to AABB’s disclosure (https://ibn.fm/N7lLb), the company had $72.0 million in cash, $30.0 million in physical gold holdings, and $2.2 million in mining properties, licenses, and concessions. Other notable assets included the value of property, plant, and equipment ($867,302), as well as earnings from the sale of AABB Gold token (“AABBG”), its digital currency backed 100% by the physical gold holdings indicated in the balance sheet. The figures provide the necessary encouragement and funding for the company to advance its gold mining and cryptocurrency operations and plans. On the gold mining front, AABB began assessing and negotiating gold mining projects during the first quarter of the year with the aim of acquiring high-yield mining and production facilities. It is currently eying two such properties in the prolific gold mining regions of Mascota and Acaponeta in Mexico (https://ibn.fm/ovwBM) and intends to accelerate the acquisition after completing drill testing, assays, and other due diligence processes. The properties, which have multiple mining sites, existing infrastructure, and production facilities capable of processing 250 tons of gold per day between them, will bring the company closer to fulfilling its strategic growth initiative to increase its physical gold holdings. The increase in physical gold holdings should strengthen Asia Broadband’s cryptocurrency operations as the company launched AABBG and AABB Wallet – both developed in collaboration with Core State Holdings Corp. (“CSHC”) – back in March. So far, Asia Broadband has accumulated $1.5 million from the sale of AABBG and has hired a marketing company to design an international marketing campaign. Geared towards increasing brand exposure, token sales, and AABB Wallet transactions, as well as boosting the public’s and investment community’s awareness of the company, the campaign will kick off towards the end of May and is expected to gather momentum over the subsequent three months. Moreover, CSHC is developing AABB’s proprietary exchange that, once completed and launched in the coming months, will allow AABB Wallet users to exchange their AABBG tokens for other cryptocurrencies such as Ethereum, Bitcoin, and Litecoin. In addition to facilitating such trades, the exchange will add significantly to the transaction fee revenues AABB already generates from its AABB Wallet and allow market forces to dictate the price of the AABBG above the minimum supported price for each token, which is equivalent to the real-time value, in dollars, of 0.1 gram of gold. As a company that is on course to fulfill its strategic goal and initiative, Asia Broadband appears poised to experience tremendous growth and performance through the remainder of 2021, guided by the successes captured in its Q1 2021 results. For more information, visit the company’s website at www.AsiaBroadbandInc.com. NOTE TO INVESTORS: The latest news and updates relating to AABB are available in the company’s newsroom at https://ibn.fm/AABB

• IBN joining forces with LD Micro to promote Invitational XI Microcap Conference
• IBN amplifies brand awareness across 5,000+ strategic distribution partners, social media network includes 2+ million followers and engagements
• LD Micro portal provides exclusive intraday information covering stocks with $50-300 million market capitalizations
• Conference features 25-minute presentations by over 180 companies, keynote speakers and thought leaders

InvestorBrandNetwork (“IBN”), an innovative corporate communications agency and diversified content distributor, recently announced that it will be collaborating with SRAX (NASDAQ: SRAX) subsidiary LD Micro for the upcoming LD Micro Invitational XI – an entirely digital three-day investor conference taking place June 8-10, 2021, on SRAX’s Sequire investor analytics SaaS platform (https://ibn.fm/3Vsof). IBN has been a proud LD Micro partner since 2012, providing an array of communications solutions that enhance visibility across its massive network that includes investors, journalists, consumers, and the general public. InvestorWire (“IW”), part of IBN’s 50+ brand network, will provide amplified brand awareness for conference participants across 5,000+ key distribution partners through wire-grade event announcement press releases, full-length promotional articles, and featured placements of the conference on a dedicated events page. IBN will also provide social media coverage via its network of branded profiles that collectively have more than 2 million likes and followers across various platforms. “We look forward to collaborating once again with Chris Lahiji and his amazing team as we work collectively to raise the visibility of some of North America’s most exciting micro and small-cap companies,” said Jonathan Keim, director of communications for IBN. “This well-experienced organization is renowned throughout the space for its innovative events, and we are very excited to continue working alongside the organizers.” Since its founding in 2006, LD Micro has grown from a newsletter into a leading event company and portal that provides exclusive intraday information covering North American stocks with market capitalizations between $50 million and $300 million. SRAX acquired the company in 2020 to accelerate the adoption of Sequire, the Company’s SaaS investor analytics platform that provides data analytics and critical insights to public companies through tools that help them monitor trading activity, track key investors, publish news, administer surveys and track warrants. Returning for its eleventh straight year, LD Micro’s Invitational XI aims to provide the company’s loyal base of investors and fans with unparalleled access to microcap companies on the verge of achieving great things in a variety of industries. Along with 25-minute presentations by over 180 companies, the conference will also feature a slate of keynote speakers, influential thought leaders and the widely anticipated LD Micro Hall of Fame – a one-day event honoring the top 50 best-performing companies out of the 2000+ that have graced the LD Micro stage. For additional details about the LD Micro Invitational Conference, including registration, visit https://ldmicrojune2021.mysequire.com For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

Live Streaming Event Date: 8, 9, 10 June 2021 Companies, individuals, and investors of the small-cap trading community are invited to attend the LD Micro Invitational XI Virtual Event being held from June 8th – 10th, 2021. Organized by SRAX’s LD Micro, this conference is attended by respected industry leaders of the micro-cap sector. Operational since 2006, LD Micro serves as a resourceful event that brings together the microcap trading companies and potential investors and shareholders on a consolidated platform. This event is expected to include 180 companies that can convene, learn and share opinions on a wide range of industry-related topics, and get deep-industry insights from influential keynote speakers and leading personalities of the micro-cap segment. The 3-day itinerary of the event is as follows:

• Day 1

8th June- Celebration of The LD Micro Hall of Fame, a key attraction of the event,  that features some of the top-performing companies in its history.

• Day 2, Day 3

9th and 10th June- 25-minutes presentation slots are allocated to upcoming companies to get a glimpse into their future aspirations. No Q&A sessions. SRAX (NASDAQ: SRAX), a financial technology company engaged in creating a consumer-managed data marketplace where people can unlock the investor data, through their premier investor intelligence and communications platform Sequire. Companies can get time data about the investors’ buying and selling behaviors and trends, and leverage the information to engage shareholders through multiple marketing channels. The company’s robust technology is being applied by brands to analyze and understand investor movement and take steps to stay ahead in the competitive curve. For more details regarding the event, please visit https://ibn.fm/4nVzq. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Pure Extracts’ BC facility is fully operational, ready to meet increasing demand for cannabis-based gummies, vapes, white label products
• Company’s involvement in functional, psychoactive mushrooms space is also gaining steam
• Pure Extracts’ current R&D focus is on psychoactive mushroom compounds

Although the global pandemic extended its sales cycle, Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) is seeing interest from producers and brands looking for new opportunities and partnerships. Pure Extracts’ CEO Ben Nikolaevsky recently released a corporate update focused on three main points of interest — cannabis, functional mushrooms and psilocybin — in its growing business (https://ibn.fm/0v5sO). The update noted that Pure Extracts’ Pemberton, British Columbia, facility is fully operational and ready to meet the increasing demand for cannabis-based gummies, vapes and white label products. The facility will be heavily involved as the company ramps up production on its Pure Pulls and Pure Chews as they re-enter the market. “We have an excellent informational/educational program in place, which is specifically designed to familiarize the retail bud tenders with the benefits and features of our historically popular product lineup,” Nikolaevsky stated. In addition, the BC facility is a key piece in Pure Extracts move to enter the U.S. market via a Michigan-based joint venture. The company signed a letter of intent with an Oregon-based multistate operator (“MSO”); the definitive agreement is in the process of being finalized. In addition to producing its own branded products for the venture, Pure Extracts is planning to produce white label products for its MSO partner as well as smaller companies in the area; the company may even license other established, out-of-state brands for the Michigan market. “Michigan is a massive green-field market that Pure Extracts can readily launch into, both from establishing our Pure Pulls and Pure Chews brands, and also in an attempt to achieve a dominant position as a leading regional extractor as well as serve as our beachhead for expansion into other cannabis approved states,” noted Nikolaevsky. “Michigan is growing at 800% year-over-year, and we believe we are ideally positioned to capture a meaningful share of the region’s growing edible and vape market.” And that’s only the tip of the cannabis iceberg. The company is growing its gummie product proprietary packaging business and has kicked off first tolling contract with a high-quality hemp grower. In addition, “white labeling has also begun to build momentum and gain sales traction for us,” said Nikolaevsky. “We are in the final stages of bringing on two large Licensed Producers as customers in order to manufacture their cannabis 2.0 products in the vape and tincture sectors.” The company’s involvement in the functional and psychoactive mushrooms space is also gaining steam. “We have successfully launched our functional wellness line of products through our Pure Mushrooms-branded Amazon direct-to-consumer sales channels in the U.S. and Canada,” Nikolaevsky said. The platform initially launched with two products — Reishi and Maitake — with plans in place to add a Lion’s Mane product later this quarter. The company’s current R&D focus is on psychoactive mushroom compounds, a focus that has been slowed because of the difficulty in obtaining psychedelic biomass, which is highly regulated by Health Canada. In fact, Nikolaevsky pointed out, many people have reported that there is little or no product available for R&D purposes. Pure Extracts was able to enter into an agreement with ShroomBloom, a British Columbia-based psychedelic mushroom cultivator that will be able to provide the company with ample product for its R&D efforts. Also in the research & development vein, the company is partnering with Psyence Group (CSE: PSYG), a company recognized for its strong R&D and production capabilities. “Psyence currently has clinical trial opportunities with two major Canadian universities for the use of psilocybin in palliative care, and through our JV, we will have access to Psyence’s team of doctors and researchers in Toronto, South Africa and Jamaica,” Nikolaevsky said. “This additional effort will prove invaluable as we work to formulate a psilocybin compound that will be fast-acting and effective in dealing with PTSD, anxiety and other mental illnesses.” “In conclusion, although COVID-19 has lengthened our sales cycle somewhat, we are now enjoying renewed interest from producers and brands looking for new opportunities and partnerships,” Nikolaevsky concluded. “We are all extremely excited to be working together to unlock the potential value of what could soon be a continent-wide industry and an opportunity totally unique to our lifetime.” Pure Extracts Technologies Corp., headquartered in Pemberton, British Columbia, is a plant-based extraction company with a new vertical in functional mushrooms. The company is positioned to an extraction leader in the rapid development and commercialization of functional and medicinal psychedelic products. For more information, visit the company’s website at www.PureExtractsCorp.com. NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL